Intellia Therapeutics, Inc.NTLANASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending higher, below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-354.66M
↓ 112% below average
Average (9y)
$-167.31M
Historical baseline
Range
High:$29.94M
Low:$-408.07M
CAGR
+63.2%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-354.66M | +13.1% |
| 2023 | $-408.07M | -4.2% |
| 2022 | $-391.68M | -64.7% |
| 2021 | $-237.79M | -344.5% |
| 2020 | $-53.50M | +51.4% |
| 2019 | $-110.03M | -62.7% |
| 2018 | $-67.61M | +10.3% |
| 2017 | $-75.37M | -351.7% |
| 2016 | $29.94M | +793.6% |
| 2015 | $-4.32M | - |